|
|
t-NanoCpG |
|
Vaxjo ID |
273 |
|
Vaccine Adjuvant Name |
t-NanoCpG |
|
Alternative Names |
ApoE-targeted CpG nano-immunoadjuvant |
|
Adjuvant VO ID |
VO_0005761
|
|
Description |
A CpG ODN-loaded, ApoE-decorated disulfide-crosslinked polymersome, designed for brain-targeted immunotherapy via i.v. or intranasal delivery |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Structure |
Nanoparticle (~44 nm) composed of PEG-polycarbonate-spermine polymers + ApoE peptide + CpG |
|
Appearance |
Likely a clear/stable colloidal solution (not visually described) |
|
Storage |
Stable for at least 7 days in 10% FBS |
|
Preparation |
Self-assembled in aqueous solution from polymer components and CpG; CpG is electrostatically loaded (~93.2% efficiency) |
|
Dosage |
0.5–2 mg/kg i.v. or 0.5 mg/kg intranasally on days 4, 6, 8 or 4, 9, 14 post-tumor implantation |
|
Function |
Intriguingly, both intravenous and intranasal administration of t-NanoCpG brings about significant survival benefits in murine LCPN glioma-bearing mice while free CpG and nontargeted CpG nano-immunoadjuvant (NanoCpG) afford modest therapeutic effects |
|
Safety |
Well tolerated; no significant toxicity or inflammation in liver, kidney, or other organs; safe via i.v. or intranasal routes |
| References |
Wei et al., 2022: Wei J, Wu D, Zhao S, Shao Y, Xia Y, Ni D, Qiu X, Zhang J, Chen J, Meng F, Zhong Z. Immunotherapy of Malignant Glioma by Noninvasive Administration of TLR9 Agonist CpG Nano-Immunoadjuvant. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2022; 9(13); e2103689. [PubMed: 35253404].
|
|
